Biogen Alzheimer’s Drug Faces FDA Panel With Billions at Stake

(Bloomberg) -- Biogen Inc.’s big bet that U.S. regulators will approve its experimental drug for Alzheimer’s disease faces a key test next week when a panel of outside advisers reviews results from...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.